Ligand Pharmaceuticals Incorporated Modification Agreements

18 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
First Amendment to Development Funding and Royalties Agreement between Ligand Pharmaceuticals Incorporated and Palvella Therapeutics, Inc.
Modification Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
2024
Second Call Option Amendment Agreement between Ligand Pharmaceuticals Incorporated and Goldman Sachs & Co. LLC (January 28, 2021)
Modification Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
NY
2021
Second Call Option Amendment Agreement between Ligand Pharmaceuticals Incorporated and Deutsche Bank AG, London Branch (January 28, 2021)
Modification Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
NY
2021
Second Call Option Amendment Agreement between Ligand Pharmaceuticals Incorporated and Barclays Bank PLC
Modification Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
NY
2021
Call Option Amendment Agreement between Ligand Pharmaceuticals Incorporated and Goldman Sachs & Co. LLC (April 6, 2020)
Modification Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
NY
2020
Call Option Amendment Agreement between Ligand Pharmaceuticals Incorporated and Deutsche Bank AG, London Branch (April 6, 2020)
Modification Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
NY
2020
Call Option Amendment Agreement between Ligand Pharmaceuticals Incorporated and Barclays Bank PLC (April 6, 2020)
Modification Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
NY
2020
First Amendment to Loan and Security Agreement between Viking Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Modification Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
2015
Amendment to TR Beta Contingent Value Rights Agreement among Ligand Pharmaceuticals, Metabasis Therapeutics, Stockholders’ Representative, and Computershare Inc.
Modification Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
2014
Amendment to General Contingent Value Rights Agreement among Ligand Pharmaceuticals, Metabasis Therapeutics, Stockholders’ Representative, and Computershare Inc.
Modification Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
2014
First Amendment to 2006 Preferred Shares Rights Agreement between Ligand Pharmaceuticals and Computershare Shareowner Services
Modification Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
2013
Sixth Amendment to Loan and Security Agreement by and among Oxford Finance LLC, Lenders, and Ligand Pharmaceuticals Incorporated
Modification Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
CA
2013
First Amendment to Loan and Security Agreement between Ligand Pharmaceuticals and Oxford Finance
Modification Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
CA
2011
Amendment to General Contingent Value Rights Agreement among Ligand Pharmaceuticals, Metabasis Therapeutics, and Others
Modification Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
2011
Amendment to Restricted Stock Agreement between Ligand Pharmaceuticals Incorporated and John L. Higgins
Modification Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
2008
Amendment to Restricted Stock Agreement between Ligand Pharmaceuticals Incorporated and Participant
Modification Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
2008
Amendment to Agreement Among Ligand Pharmaceuticals, Seragen, and Eli Lilly Regarding Royalty Buy-Down Options
Modification Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
IN
2005
Amendment No. 1 to Option Agreement among Ligand Pharmaceuticals, Royalty Pharma Finance Trust, and Investors Trust & Custodial Services (Ireland) Ltd.
Modification Agreements
Ligand Pharmaceuticals Incorporated
Biotechnology
NY
2005